Skip to main content
OpenTrials

Clinical trial condition

Secondary Acute Myeloid Leukemia

Explore clinical trials studying Secondary Acute Myeloid Leukemia. Study availability and eligibility vary by location and protocol.

116 public trials 8 recruiting studies
Refine in advanced search Browse all conditions

Secondary Acute Myeloid Leukemia trial results

Completed

Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications

NCT00799461

Conditions
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, +154 more
Locations
  • Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium Seattle, Washington, United States
View Trial Details
Active, Not Recruiting

Hu8F4 in Treating Patients With Advanced Hematologic Malignancies

NCT02530034

Conditions
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Blast Crisis, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, +31 more
Locations
  • Augusta University Augusta, Georgia, United States
  • Montefiore Medical Center, Albert Einstein College of Medicine The Bronx, New York, United States
  • M D Anderson Cancer Center Houston, Texas, United States
  • Huntsman Cancer Institute Salt Lake City, Utah, United States
View Trial Details
Active, Not Recruiting

Azacitidine and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia

NCT00658814

Conditions
Acute Myeloid Leukemia, Adult Acute Megakaryoblastic Leukemia, Adult Acute Monoblastic Leukemia, +24 more
Locations
  • Providence Saint Joseph Medical Center/Disney Family Cancer Center Burbank, California, United States
  • Stanford Cancer Institute Palo Alto Palo Alto, California, United States
  • University of California Davis Comprehensive Cancer Center Sacramento, California, United States
  • Smilow Cancer Hospital Care Center at Saint Francis Hartford, Connecticut, United States
View all 177 locations
View Trial Details
Active, Not Recruiting

BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia

NCT04214249

Conditions
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia Post Cytotoxic Therapy, +8 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • UC Irvine Health/Chao Family Comprehensive Cancer Center Orange, California, United States
  • Yale University New Haven, Connecticut, United States
  • Mayo Clinic in Florida Jacksonville, Florida, United States
View Trial Details
Active, Not Recruiting

Testing a New Chemotherapy Drug, KRT-232 (AMG-232) in Combination With Decitabine and Venetoclax in Patients With Acute Myeloid Leukemia

NCT03041688

Conditions
Acute Myeloid Leukemia, Hematologic Diseases, Hemic and Lymphatic Diseases, +8 more
Locations
  • City of Hope Comprehensive Cancer Center Duarte, California, United States
  • Los Angeles General Medical Center Los Angeles, California, United States
  • USC / Norris Comprehensive Cancer Center Los Angeles, California, United States
  • Keck Medical Center of USC Pasadena Pasadena, California, United States
View all 13 locations
View Trial Details
Active, Not Recruiting

BLAST MRD AML-2: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Azacitidine and Venetoclax as Frontline Therapy in Unfit Patients With Acute Myeloid Leukemia

NCT04284787

Conditions
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia Post Cytotoxic Therapy, +8 more
Locations
  • Smilow Cancer Hospital Care Center at Greenwich Greenwich, Connecticut, United States
  • Smilow Cancer Hospital Care Center at Saint Francis Hartford, Connecticut, United States
  • Yale University New Haven, Connecticut, United States
  • MedStar Georgetown University Hospital Washington D.C., District of Columbia, United States
View all 29 locations
View Trial Details

Related conditions